Cargando…

Reverse effect of Semaphorin-3F on rituximab resistance in diffuse large B-cell lymphoma via the Hippo pathway

BACKGROUND: Exploring the underlying mechanism of rituximab resistance is critical to improve the outcomes of patients with diffuse large B-cell lymphoma (DLBCL). Here, we tried to identify the effects of the axon guidance factor semaphorin-3F (SEMA3F) on rituximab resistance as well as its therapeu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Qiong, Ma, Naya, Li, Xinlei, Yang, Chao, Zhang, Wei, Xiong, Jingkang, Zhu, Lidan, Li, Jiali, Wen, Qin, Gao, Lei, Yang, Cheng, Rao, Lingyi, Gao, Li, Zhang, Xi, Rao, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278727/ https://www.ncbi.nlm.nih.gov/pubmed/37114652 http://dx.doi.org/10.1097/CM9.0000000000002686

Ejemplares similares

The Novel Prognostic Index Model of Combining Circulating Tumor DNA and PINK-E Predicts the Clinical Outcomes for Newly Diagnosed Extranodal NK/T-cell Lymphoma
por: Huang, Dezhi, et al.
Publicado: (2022)

The Hippo pathway mediates Semaphorin signaling
por: Meng, Zhipeng, et al.
Publicado: (2022)

PB2302: A TRNA-DERIVED SMALL RNAS EXPRESSION SIGNATURE AS A PREDICTIVE AND PROGNOSTIC BIOMARKER IN DIFFUSE LARGE B CELL LYMPHOMA
por: Rao, Jun, et al.
Publicado: (2023)

Plasma circulating tumor DNA assessment reveals KMT2D as a potential poor prognostic factor in extranodal NK/T-cell lymphoma
por: Li, Qiong, et al.
Publicado: (2020)

Plasmacytoid Dendritic Cell Infiltration in Acute Myeloid Leukemia
por: Zhu, Lidan, et al.
Publicado: (2020)

Serum semaphorin4C as an auxiliary diagnostic biomarker for breast cancer
por: Wang, Ya, et al.
Publicado: (2021)

Primary breast diffuse large B‐cell lymphoma in the rituximab era: Therapeutic strategies and patterns of failure
por: Hu, Shaoxuan, et al.
Publicado: (2018)

Efficacy of rituximab combined with CHOP for treating patients with diffuse large B-cell lymphoma
por: Hu, Xin, et al.
Publicado: (2017)

Rituximab maintenance therapy for patients with diffuse large B-cell lymphoma: A meta-analysis
por: Zhou, Xuan, et al.
Publicado: (2017)

Regulation of Hippo-YAP signaling by insulin-like growth factor-1 receptor in the tumorigenesis of diffuse large B-cell lymphoma
por: Zhou, Xiangxiang, et al.
Publicado: (2020)

Primary breast diffuse large B-cell lymphoma in the era of rituximab
por: Zhang, Na, et al.
Publicado: (2016)

A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma
por: Shi, Yuankai, et al.
Publicado: (2020)

PB2079: LACTATE DECREASES BORTEZOMIB SENSITIVITY AND PREDICTS POOR CLINICAL OUTCOMES OF MULTIPLE MYELOMA
por: MA, Naya, et al.
Publicado: (2023)

The adhesion molecule ICAM-1 in diffuse large B-cell lymphoma post-rituximab era: relationship with prognostic importance and rituximab resistance
por: Liu, Yizhen, et al.
Publicado: (2020)

Semaphorins and Their Receptors in Hematological Malignancies
por: Wei, Li, et al.
Publicado: (2019)

The semaphorins
por: Yazdani, Umar, et al.
Publicado: (2006)

Rituximab-induced HMGB1 release is associated with inhibition of STAT3 activity in human diffuse large B-cell lymphoma
por: Zhao, Tiansuo, et al.
Publicado: (2015)

Subcutaneous Rituximab in Follicular Lymphoma, Chronic Lymphocytic Leukemia, and Diffuse Large B-Cell Lymphoma
por: Yelvington, Bradley J.
Publicado: (2018)

The Role of Semaphorins in Metabolic Disorders
por: Lu, Qiongyu, et al.
Publicado: (2020)

Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival
por: Chen, Kai-Lin, et al.
Publicado: (2015)

Advances in single-cell RNA sequencing and its applications in cancer research
por: Huang, Dezhi, et al.
Publicado: (2023)

Role of Semaphorins in Ischemic Stroke
por: Du, Huaping, et al.
Publicado: (2022)

The Role of Semaphorin 3A in Bone Remodeling
por: Li, Zhenxia, et al.
Publicado: (2017)

Progressive dyspnea and diffuse ground‐glass opacities after treatment for lymphoma with rituximab‐containing chemotherapy: A case report
por: Sun, Yuxin, et al.
Publicado: (2020)

Lenalidomide plus rituximab Vs rituximab alone in relapsed or refractory indolent lymphoma: A cost‐effectiveness analysis
por: Zhang, Peng‐Fei, et al.
Publicado: (2020)

PB2307: PHARMACOKINETICS, EFFICACY AND SAFETY OF SUBCUTANEOUS VERSUS INTRAVENOUS RITUXIMAB COMBINED WITH CHOP IN CHINESE PATIENTS WITH UNTREATED CD20-POSITIVE DIFFUSE LARGE B CELL LYMPHOMA: A RANDOMIZED TRIAL
por: Gao, Yan, et al.
Publicado: (2023)

Tandem autologous hematopoietic stem cell transplantation for treatment of adult T-cell lymphoblastic lymphoma: a multiple center prospective study in China
por: Liu, Yao, et al.
Publicado: (2019)

Increased interleukin-17A levels promote rituximab resistance by suppressing p53 expression and predict an unfavorable prognosis in patients with diffuse large B cell lymphoma
por: Zhong, Weijie, et al.
Publicado: (2018)

Maintenance rituximab in Veterans with follicular lymphoma
por: Halwani, Ahmad S., et al.
Publicado: (2020)

P1163: ZANUBRUTINIB PLUS RITUXIMAB AND LENALIDOMIDE (ZR2) FOR RELAPSED AND REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
por: Zhang, Xiyuan, et al.
Publicado: (2023)

Rituximab Treatment Strategy for Patients with Diffuse Large B-Cell Lymphoma after First-Line Therapy: A Systematic Review and Meta-Analysis
por: Ren, Yuan-Rong, et al.
Publicado: (2015)

Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma
por: Vacirca, Jeffrey L., et al.
Publicado: (2013)

The Kyoto Prognostic Index for patients with diffuse large B-cell lymphoma in the rituximab era
por: Kobayashi, T, et al.
Publicado: (2016)

The effectiveness of rituximab and HIV on the survival of Ontario patients with diffuse large B‐cell lymphoma
por: Habbous, Steven, et al.
Publicado: (2020)

Monoclonal Antibodies in the Treatment of Diffuse Large B-Cell Lymphoma: Moving beyond Rituximab
por: Papageorgiou, Sotirios G., et al.
Publicado: (2022)

Role of radiation therapy in primary breast diffuse large B‐cell lymphoma in the Rituximab era: a SEER database analysis
por: Liu, Pan‐pan, et al.
Publicado: (2018)

P1224: EFFICACY OF RITUXIMAB AND BIOSIMILAR RITUXIMAB IN UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA, A DANISH POPULATION BASED ANALYSIS
por: Haujir, A., et al.
Publicado: (2022)

IDO, TDO, and AHR overexpression is associated with poor outcome in diffuse large B-cell lymphoma patients in the rituximab era
por: Chen, Xiangli, et al.
Publicado: (2020)

Reverse Signaling by Semaphorin-6A Regulates Cellular Aggregation and Neuronal Morphology
por: Perez-Branguli, Francesc, et al.
Publicado: (2016)

Architecture, substructures, and dynamic assembly of STRIPAK complexes in Hippo signaling
por: Tang, Yang, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_m0oq2679u5ov7ags96kkl017qg